Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

2022-12-01
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepointsAdaptive now accepts blood samples from DLBCL patients in Streck® tubes that stabilize ctDNA SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

2022-11-21
SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Wednesday, Novemb

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results

2022-11-21
>95% of patients who had an MRD test describe that MRD testing helped inform treatment decisions or brought comfort in their treatment journey85% of surveyed patients have heard of MRD testing, yet only 47% report having had an MRD test, highlighting an opportunity to expand education to benefit more patients SEATTLE and SALT LAKE CITY, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the geneti

Adaptive Biotechnologies (ADPT) Investor presntation - Slideshow

2022-11-16
The following slide deck was published by Adaptive Biotechnologies Corporation in conjunction with this event.

Society for Immunotherapy of Cancer to hold a meeting

2022-11-11
37th Annual Meeting SITC ... ABMD, ADPT, ALKS, AMGN, ASND, BMY, CGEN, CLRB, CRL, INKT, INCY, PHIO, INBX, XNCR, VCYT, TXG, TPST, TMO, TIL, SGEN, REGN, REPL, RHHBY, DNA, CUE, IOVA, IPSC, LH, MRK, MXCT, EXEL, FATE, GMAB

J.P. Morgan Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)

2022-11-07
J.P. Morgan analyst Julia Qin maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) on November 4 and set a price target of $18.00. The...

BTIG Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)

2022-11-06
BTIG analyst Mark Massaro reiterated a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) yesterday and set a price target of $13.00. The company...

5 Top Stocks Cathie Wood Is Buying This Week

2022-11-04
Cathie Wood just lauded Elon Musk's acquisition of Twitter, believing the platform will become a "super-app." Here are her top five buys.

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates

2022-11-03
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

2022-11-03
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2022. “We continue to deliver solid growth in both of our business areas quarter over quarter, and are confident in our long-term outlook,” said